Food intake regulating hormones in adult craniopharyngioma patients

Roemmler-Zehrer, Josefine; Geigenberger, Veronika; Störmann, Sylvère; Losa, Marco; Crippa, Valentina; Otto, Bärbel; Bidlingmaier, Martin; Dimopoulou, Christina; Stalla, Günter; Schopohl, Jochen

doi:10.1530/eje-13-0832

Cited by 19 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on PYY in BBS were lacking. In obesity due to craniopharyngioma , fasting and postprandial PYY concentrations were not different compared to controls in children and adults ( 12 , 21 , 22 , 65 ).…”

Section: Neuroendocrine Factors Inhibiting Food Intake and Body Weightmentioning

confidence: 70%

“…In BBS ( 20 ) and in craniopharyngioma patients ( 21 , 23 , 24 , 63 , 64 , 65 , 66 ), fasting leptin was also higher, even after correction for BMI. In craniopharyngioma patients, higher levels are reported in patients with hypothalamic involvement compared to those without hypothalamic involvement, which may be the result of central dysregulation due to the hypothalamic damage ( 21 , 23 , 63 , 66 ).…”

Section: Neuroendocrine Factors Inhibiting Food Intake and Body Weightmentioning

confidence: 93%

See 1 more Smart Citation

Appetite- and weight-inducing and -inhibiting neuroendocrine factors in Prader–Willi syndrome, Bardet–Biedl syndrome and craniopharyngioma versus anorexia nervosa

Vlaardingerbroek

Akker

Hokken-Koelega

2021

Endocrine Connections

View full text Add to dashboard Cite

Obesity is reaching endemic state and has a major impact on health and economy. In most cases obesity is caused by life style factors. However, the risk of becoming obese differs highly between people. Individual differences in life style, genetic, and neuroendocrine factors play a role in satiety, hunger and regulation of body weight. In a small percentage of children and adults with obesity, an underlying hormonal or genetic cause can be found. The aim of this review is to present and compare data on the extreme ends of the obesity and undernutrition spectrum in patients with Prader-Willi syndrome (PWS), Bardet-Biedl syndrome (BBS), acquired hypothalamic obesity in craniopharyngioma patients, and anorexia nervosa. This may give more insight in the role of neuroendocrine factors and might give direction for future research in conditions of severe obesity and underweight.

show abstract

Section: Neuroendocrine Factors Inhibiting Food Intake and Body Weightmentioning

confidence: 70%

Section: Neuroendocrine Factors Inhibiting Food Intake and Body Weightmentioning

confidence: 93%

Appetite- and weight-inducing and -inhibiting neuroendocrine factors in Prader–Willi syndrome, Bardet–Biedl syndrome and craniopharyngioma versus anorexia nervosa

Vlaardingerbroek

Akker

Hokken-Koelega

2021

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…(2014) a 95 39 Total Increased* NR NR CP and pituitary Holmer et al . (2010) 42 42 Total Decreased* NR Inverse* Roemmler-Zehrer et al . (2014) 40 40 f Total Decreased* NR NR Roth et al .…”

Section: Resultsmentioning

confidence: 99%

“…Four studies investigated ghrelin levels in patients with craniopharyngioma (CP) – which is associated with obesity, metabolic syndrome and GH deficiency – and pituitary cancer ( Trivin et al 2009 , Holmer et al 2010 , Roth et al 2011 , Roemmler-Zehrer et al 2014 ) ( Table 1 ). Three of the studies reported significantly reduced ghrelin levels in CP patients vs controls ( Holmer et al 2010 , Roth et al 2011 , Roemmler-Zehrer et al 2014 ), and two reported a significant inverse association of serum ghrelin level with CP tumor growth ( Trivin et al 2009 , Holmer et al 2010 ). While two of these studies were controlled by age and gender but not BMI ( Holmer et al 2010 , Roemmler-Zehrer et al 2014 ), the one study that did match CP patients ( n =27) and controls ( n =27) for BMI as well as age and gender found that obese CP patients had lower ghrelin levels than obese controls ( Roth et al 2011 ).…”

Section: Resultsmentioning

confidence: 99%

Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review

Sever¹,

White²,

García³

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Ghrelin is a hormone with multiple physiologic functions, including promotion of growth hormone release, stimulation of appetite and regulation of energy homeostasis. Treatment with ghrelin/ghrelin-receptor agonists is a prospective therapy for disease-related cachexia and malnutrition. In vitro studies have shown high expression of ghrelin in cancer tissue, although its role including its impact in cancer risk and progression has not been established. We performed a systematic literature review to identify peer-reviewed human or animal in vivo original research studies of ghrelin, ghrelin-receptor agonists, or ghrelin genetic variants and the risk, presence, or growth of cancer using structured searches in PubMed database as well as secondary searches of article reference lists, additional reviews and meta-analyses. Overall, 45 (73.8%) of the 61 studies reviewed, including all 11 involving exogenous ghrelin/ghrelin-receptor agonist treatment, reported either a null (no statistically significant difference) or inverse association of ghrelin/ghrelin-receptor agonists or ghrelin genetic variants with cancer risk, presence or growth; 10 (16.7%) studies reported positive associations; and 6 (10.0%) reported both negative or null and positive associations. Differences in serum ghrelin levels in cancer cases vs controls (typically lower) were reported for some but not all cancers. The majority of in vivo studies showed a null or inverse association of ghrelin with risk and progression of most cancers, suggesting that ghrelin/ghrelin-receptor agonist treatment may have a favorable safety profile to use for cancer cachexia. Additional large-scale prospective clinical trials as well as basic bioscientific research are warranted to further evaluate the safety and benefits of ghrelin treatment in patients with cancer.

show abstract

“…Roemmler-Zehrer and colleagues [ 84 ▪ ] recently analysed the gastrointestinal hormones ghrelin and peptide YY and their effect on satiety in obese craniopharyngioma patients. Their findings support the hypothesis that reduced ghrelin secretion and reduced postprandial suppression of ghrelin and severe obesity leads to disturbed regulation of appetite in craniopharyngioma patients.…”

Section: Hypothalamic Obesitymentioning

confidence: 99%

Craniopharyngioma and hypothalamic injury

Müller

2016

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of reviewHypothalamic alterations, pathological or treatment induced, have major impact on prognosis in craniopharyngioma patients mainly because of consequent hypothalamic obesity. Recent insight in molecular genetics, treatment strategies, risk factors and outcomes associated with hypothalamic obesity provide novel therapeutic perspectives. This review includes relevant publications since 2013.Recent findingsRecent findings confirm that alterations in posterior hypothalamic areas because of tumour location and/or treatment-related injuries are associated with severe hypothalamic obesity, reduced overall survival and impaired quality of life in long-term survivors of childhood-onset craniopharyngioma. However, eating disorders are observed because of hypothalamic obesity without clear disease-specific patterns. Treatment options for hypothalamic obesity are very limited. Treatment with invasive, nonreversible bariatric methods such as Roux-en-Y gastric bypass is most efficient in weight reduction, but controversial in the paediatric population because of medical, ethical, and legal considerations. Accordingly, treatment in craniopharyngioma should focus on prevention of (further) hypothalamic injury. Presurgical imaging for grading of hypothalamic involvement should be the basis for hypothalamus-sparing strategies conducted by experienced multidisciplinary teams.SummaryUntil a nonsurgical therapeutic option for hypothalamic obesity for paediatric patients is found, prevention of hypothalamic injury should be the preferred treatment strategy, conducted exclusively by experienced multidisciplinary teams.

show abstract

Food intake regulating hormones in adult craniopharyngioma patients

Cited by 19 publications

References 46 publications

Appetite- and weight-inducing and -inhibiting neuroendocrine factors in Prader–Willi syndrome, Bardet–Biedl syndrome and craniopharyngioma versus anorexia nervosa

Appetite- and weight-inducing and -inhibiting neuroendocrine factors in Prader–Willi syndrome, Bardet–Biedl syndrome and craniopharyngioma versus anorexia nervosa

Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review

Craniopharyngioma and hypothalamic injury

Contact Info

Product

Resources

About